The DOI matches its Crossref record.
Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD
Open accessAbstract
Steroid-refractory acute GVHD (SR-GVHD) remains a significant complication of allogeneic hematopoietic cell transplantation (HCT). Prochymal® (Mesenchymal Stem Cells, MSC, derived from unrelated volunteer adult donors) was evaluated in addition to standard of care, including institutionally selected second line treatment, in a randomized (2:1) trial in patients with SR-GVHD (Protocol 280). Patients received 8 infusions of 2 × 106 MSC/kg over 4 weeks (or volume equivalent for placebo), with an additional 4 infusions administered weekly after day 28 in patients who had a partial response, defined as improvement in at least one organ without progression in others. The primary endpoint was durable complete response (DCR) for≥28 days. Additional prospectively defined outcomes included responses in patients by organ involvement. P-values were based on Chi-square tests, unless otherwise specified. 244 patients with SR-GVHD (skin involvement n=144, GI involvement n=179, liver involvement n=61) were enrolled and treated on study: Prochymal (n=163), placebo (n=81). There were no significant differences in age, pre-transplant conditioning, graft source, HLA-matching or second-line therapy between treatment arms. For the Prochymal and placebo arms, respectively, the grades of GVHD at entry were B (22% vs. 26%), C (51% vs. 58%), and D (27% vs. 16%). The respective DCR rates were 35% vs. 30% (p=0.3) in the ITT population and 40% vs. 28% (p=0.08) in the per protocol population. Results for secondary endpoints are shown in the table. Patients with GvHD affecting all 3 organs had overall complete or partial responses rate of 63% vs. 0% (n=22, p<0.05, Fisher's exact test) at day 28. Patients treated with Prochymal had less progression of liver GVHD at weeks 2 and 4 respectively (32% vs 59%, p=0.05; and 37% vs. 65%, p=0.05). The incidence of infections was not different between arms. Incidence rates were 9% vs. 8% for recurrent malignancy, 1.8% vs. 2.5% for infusional toxicity, and 0.6% vs. 4.6% for discontinuation due to an AE in Prochymal versus Placebo, respectively. GVHD with liver or gut involvement is a life-threatening complication of HCT. Our results suggest that the addition of Prochymal produced significant improvement without additive toxicity in patients with SR-GVHD involving visceral organs.Tabled 1Overall Complete or Partial Response Rates in Patients According to Organ InvolvementDay 100 Response RateOrganProchymalPlaceboOdds Ratio95% CIP ValueOverall82%73%1.70.9-3.10.12Skin78%77%1.10.5-2.40.9Liver76%47%3.61.1-11.2<0.05Gut82%68%2.21.1-4.4<0.05 Open table in a new tab
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Bianco, P. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013132 · Cited by 402
Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells
Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010) · Stem Cells · doi:10.1002/stem.459 · Cited by 376
Diagnosis and management of acute graft‐versus‐host disease
Dignan, F. L., Clark, A., Amrolia, P., Cornish, J., Jackson, G., Mahendra, P., Scarisbrick, J. J., Taylor, P. C., Hadzic, N., Shaw, B. E., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09129.x · Cited by 314
Regmi, S., Pathak, S., Kim, J. O., Yong, C. S., & Jeong, J.-H. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.04.002 · Cited by 314
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
Kuci, Z., Bonig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., kifi, M., Michel, K., Eising, B., Lucchini, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140368 · Cited by 118
Blanc, K. L., Dazzi, F., English, K., Farge, D., Galipeau, J., Horwitz, E. M., Kadri, N., Krampera, M., Lalu, M. M., Nolta, J., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.01.005 · Cited by 48
Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Metadata
- Authors
- Martin, P. J., Uberti, J. P., Soiffer, R. J., Klingemann, H., Waller, E. K., Daly, A. S., Herrmann, R. P., & Kebriaei, P.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 16
- Issue
- 2
- Pages
- S169-S170
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2141841695
- Cited by
- 176
- References
- 0
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.